CSI Market
Sign In | Register

Pandion Therapeutics Inc (PAND) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access PAND Annual Income Statement →
Income statement data covering Pandion Therapeutics Inc–Dec 31 2019 offers a view into how Dec 31 2020's operating results have moved alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2020)
Q4 2020 		(Sep 30 2020) (Jun 30 2020) (Mar 31 2020) (Dec 31 2019)
Revenues
Sales of Products0.00
Total Revenue2.19
Costs & Expenses
Gross Profit-4.59
Selling, Administration, Marketing6.63
Depreciation & Amortization0.00
Research and Development Expense18.15
Other Operating Expense / -Income-49.56
Total operating costs including COS-24.78
Operating income / -loss20.19
Interest Expense0.29
Interest Income0.00
Net Interest (-)Expense / Income-0.29
Investment Income, Interest0.00
Other loss / -income-0.57
Total costs & expenses-25.06
Income & Taxes
Income / -loss before income taxes20.47
Income after income taxes20.47
Income / -loss from continuing operations20.47
Preferred dividends3.38
Net income / -loss20.47
Income / -loss to shareholder-11.22
EBIT20.76
EBITD20.94
EBITDA20.94
Earnings Per Share
Basic EPS (excl. extra items)-0.83
Basic Net EPS-0.83
Basic shares outstanding (Mill. of Units)13.55
Diluted Net EPS-0.83
Diluted average shares (Mill. of Units)13.55
4 historic quarters locked

Sign in to unlock the full Pandion Therapeutics Inc income statement history.

Sign In Create Free Account

About PAND Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.